Speaker: Shirish Gadgeel

1:23:36

Dr. Shirish Gadgeel, MD

0:34:29

Shirish M. Gadgeel, MD: SCLC in 2024

0:42:35

15th WCLC - Treatment (Moderator P. Bunn) Presenters: Q. Zhou, R. Rintoul, G. Masters, S. Gadgeel

0:05:20

Blood first assay screening in treatment-naïve NSCLC: initial results from the ALK+ cohort

0:03:13

Osimertinib responses after rociletinib treatment of T790M-positive NSCLC

0:02:57

FGFR driver genetic alterations in NSCLC

0:02:39

Phase III trial of divarasib versus adagrasib or sotorasib in KRAS G12C-m NSCLC

0:01:51

Evaluating first-line therapies for EGFR-mutated NSCLC in 2024

0:27:43

Targeting the immune system with checkpoint inhibitors

0:06:15

MARIPOSA: longer-term follow-up of amivantamab & lazertinib in EGFR-m NSCLC

0:02:00

Updated Data from Phase 2 Study of Alectinib in ALK–Positive Non–Small–Cell Lung Cancer

0:02:32

Management of AEs from amivantamab and lazertinib for EGFR-m NSCLC

0:37:32

Latest updates in exon 20 insertions focusing on targeted therapies, novel approaches, and impli...

2:46:54

SWOG Fall 2022 Hybrid Group Meeting: Lung Committee

0:22:10

First and Second Generation ALK Inhibitors for the Treatment of Lung Cancer

0:01:27

Overview of the PD-1/PD-L1 research presentation

0:05:06

Subgroup analysis of OAK trial data supports use of atezolizumab in patients with NSCLC

0:01:48

Results of KEYNOTE-024 trial of pembrolizumab in NSCLC

0:00:56

Pembrolizumab and the significance of PD-L1 for lung cancer

0:03:16

KEYNOTE-057 update: pembrolizumab for high-risk NMIBC patients

0:00:57

How pembrolizumab will change the management of advanced lung cancer

0:58:12

Enigma (Elucidating Novel Immune and Genomic Markers for ALK) with Drs. Gainor and Lin.

0:56:52

Dr. Christopher Kelsey: Radiation Therapy in the Management of Small Cell Lung Cancer

0:41:35

Anti-PD1 and Anti-PDL1 strategies in NSCLC treatment algorithms